- Policy
- Reimbursed generics pour in with Xarelto's patent expiry
- by Kim, Jung-Ju Sep 24, 2021 05:57am
- More than 100 reimbursed generics of Xarelto will be pouring into the market next month with the substance patent expiry of the novel oral anticoagulant (NOAC) Xarelto (rivaroxaban). Among the drugs, products that are subject to premium pricing for being drugs from innovative pharmaceutical companies, etc. are Chong Kun Dang’s Riroxia Ta
- Policy
- Lynparza RSA renewed, adds reimbursement for ovarian cancer
- by Lee, Hye-Kyung Sep 24, 2021 05:56am
- In addition to the ongoing negotiations for RSA renewal, an insurance benefit standard will be newly established for ‘Lynparza (olaparib)’ as maintenance monotherapy. The Health Insurance Review and Assessment Service (HIRA) has announced that it has posted a public notice on the ‘Details of the standards and methods for applying insura
- Company
- Celltrion signed a contract with the U.S. for DiaTrust
- by Lee, Seok-Jun Sep 24, 2021 05:56am
- Celltrion will supply DiaTrustTM COVID-19 Rapid Test, co-developed with Humasis, an in vitro diagnostic company, to the United States through Celltrion USA. According to the company on the 23rd, Celltrion USA was finally selected as a supplier in a purchasing project conducted by DLA under the U.S. Department of Defense. As early as the 1s
- Policy
- Rekirona are expanded to 50 years of age or older
- by Lee, Tak-Sun Sep 24, 2021 05:56am
- The MFDS approved the official approval based on the results report of phase 3 clinical trials of Celltrion's COVID-19 antibody treatment Rekirona, which completed phase 3 global submitted by the company. It has expanded the subject of administration. However, mild patients were not included. The MFDS announced on the 17th that it had careful
- Company
- Trelegy Ellipta can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 23, 2021 05:44am
- The COPD treatment Trelegy Ellipta can be prescribed at general hospitals. According to related industries, GSK Korea's COPA treatment Trelegy Ellipta (Fluticasone Furoate, Umecridinium Br, Villanterol Trifenate) passed DC at 38 medical institutions including Big 5 General Hospitals such as Seoul National University Hospital and Asan Me
- Policy
- Pfizer voluntarily recalls Champix 10 days after MFDS annc.
- by Lee, Tak-Sun Sep 23, 2021 05:44am
- Some lots of Pfizer’s leading smoking cessation treatment, Champix, will be voluntarily recalled. Although the drugs were not subject to recall under the MFDS announcement on the 7th, Pfizer opted to voluntarily recall its products as the drugs exceeded the MFDS's temporary release standards. The standards that the company applied for
- Policy
- Varenicline recalls were based on Pfizer's standards
- by Lee, Tak-Sun Sep 23, 2021 05:43am
- On why the recall and lot release standards were set differently for the smoking cessation treatment ‘varenicline,’ which was found to have nitrosamine impurities, is gaining attention. This difference in standards had allowed Pfizer’s Champix from being recalled. While announcing the N-nitroso-varenicline (NNV) impurity test results
- Company
- It surpassed ₩1 trillion in monthly drug imports
- by Kim, Jin-Gu Sep 23, 2021 05:43am
- In August, pharmaceutical imports surpassed &8361;1 trillion for the first time. This is due to the fact that imports of Pfizer, Moderna vaccines were reflected in statistics following July. Drug exports rose 10% year-on-year to &8361;700 billion last month. However, as imports increased sharply around the COVID-19 vaccine, the deficit in t
- Policy
- Price for Kymriah needs a new management method
- by Lee, Hye-Kyung Sep 23, 2021 05:43am
- The NHIS continues to discuss finding a new drug price management method for the rapid registration of ultra-high-priced "one-shot treatments." However, he said he would consider the introduction of "post-registration evaluation" required by patient organizations as one of several alternatives, not the correct answer. The Guidelines for Calcu
- Company
- The once-daily Xeljanz XR lands in general hospitals
- by Eo, Yun-Ho Sep 17, 2021 05:56am
- The new extended-release formulation of Xeljanz, Xeljanz XR, has started its landing process in general hospitals. According to industry sources, Pfizer Korea’s rheumatoid arthritis treatment ‘Xeljanz XR 11mg’ passed the Drug Committees (DCs) of the Big-5s general hospitals in Korea - Seoul National University Hospital (SNUH), Asan
